HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.

AbstractBACKGROUND:
Multidrug chemotherapy (CT) is still associated with relevant side-effects. We assessed, under current practice patterns, frequency and severity of CT-induced toxicity and its economic consequences.
PATIENTS AND METHODS:
Prospective, multicentre, longitudinal, observational cohort study with lymphoproliferative disorder (LPD) and non-small-cell lung cancer (NSCLC) patients, receiving first- or second-line (immuno-) CT (excluding myeloablative CT). Data were collected from patient interviews and preplanned chart reviews. Costs in 2007 euros are presented from the provider perspective.
RESULTS:
Two hundred and seventy-three patients (n = 153 LPD; n = 120 NSCLC) undergoing a total of 1004 CT cycles were assessable (age ≥65 years, 40%; female, 36%; Eastern Cooperative Oncology Group performance status ≥2, 11%; tumour stage ≥III, 56%; history of comorbidity, 80%). Fifty percent of cycles were associated with grade 3/4 toxicity and 37% (n = 371) with at least one hospital stay (outpatient/day care n = 154; intensive care n = 19). Mean (median) toxicity-related costs amounted to €1032 (€86) per cycle. Costs rose exponentially with the number of grade 3/4 adverse drug reactions (ADRs) and were highest in cycles affected by more than four ADRs, €10 881 (€5455); in cycles with intensive care, €14 121 (€8833); and in cycles affected by grade 3/4 infections and febrile neutropenia/leukopenia, €7093 (€4531) and €5170 (€2899), respectively. Five percent of CT cycles accounted for 56% of total expenses.
CONCLUSIONS:
Individualised supportive care strategies are needed. Future research should focus on identifying toxicity clusters and patient characteristics predictive for high costs.
AuthorsB J Paessens, C von Schilling, K Berger, M Shlaen, C Müller-Thomas, R Bernard, C Peschel, A Ihbe-Heffinger
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 22 Issue 10 Pg. 2310-9 (Oct 2011) ISSN: 1569-8041 [Electronic] England
PMID21343378 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Topics
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, economics, therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, economics)
  • Cohort Studies
  • Female
  • Germany
  • Health Care Costs
  • Health Resources (economics, statistics & numerical data)
  • Humans
  • Longitudinal Studies
  • Lung Neoplasms (drug therapy, economics)
  • Lymphoproliferative Disorders (drug therapy, economics)
  • Male
  • Middle Aged
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: